{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021491","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.420748+00:00","generated_at":"2026-06-15T02:17:08.047762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lyra Therapeutics Q1 2023 net loss $16.3M; ENLIGHTEN I Phase 3 on track for 1H 2024 data","bullets":["Net loss of $16.3M for Q1 2023, compared to $11.9M in Q1 2022.","Cash, equivalents, and short-term investments $82.7M at March 31, 2023; cash runway into mid-Q2 2024.","ENLIGHTEN I Phase 3 trial (LYR-210, pre-surgical CRS) enrollment ongoing; data expected 1H 2024.","ENLIGHTEN II Phase 3 trial restarted enrollment in April 2023; completion expected H2 2024.","BEACON Phase 2 trial (LYR-220, post-surgical CRS) enrollment complete; data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021491","json":"https://secwatch.observer/filing/0000950170-23-021491.json","markdown":"https://secwatch.observer/filing/0000950170-23-021491.md","text":"https://secwatch.observer/filing/0000950170-23-021491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/0000950170-23-021491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/lyra-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:17:08.047762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de89027616db0509ba93360f00b1cf9593a8abb8","claim":"Lyra Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $16.3 million.","evidence_excerpt":"Net loss for the first quarter 2023 was $16.3 million compared to $11.9 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/0000950170-23-021491-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$16.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}